In a similar study, gefitinib-mediated cell death was suppressed in ovarian cancer cells by augmented activation of epidermal growth factor receptor (EGFR) which positively correlated with upregulation of ST6Gal-I expression [70]. Here, ST6GAL1 is linked to ovarian carcinoma.